NASDAQ:ODT - Odonate Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $17.55 +1.12 (+6.82 %) (As of 01/17/2019 11:56 AM ET)Previous Close$16.43Today's Range$16.62 - $17.5552-Week Range$11.54 - $32.00Volume10,633 shsAverage Volume103,213 shsMarket Capitalization$437.02 millionP/E Ratio-7.11Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California. Receive ODT News and Ratings via Email Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ODT Previous Symbol CUSIPN/A Webwww.odonate.com Phone858-731-8180Debt Debt-to-Equity RatioN/A Current Ratio10.90 Quick Ratio10.90Price-To-Earnings Trailing P/E Ratio-7.11 Forward P/E Ratio-5.03 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.29 per share Price / Book2.41Profitability EPS (Most Recent Fiscal Year)($2.31) Net Income$-32,740,000.00 Net MarginsN/A Return on Equity-42.85% Return on Assets-40.38%Miscellaneous Employees60 Outstanding Shares26,830,000Market Cap$437.02 million OptionableNot Optionable Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions What is Odonate Therapeutics' stock symbol? Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT." How were Odonate Therapeutics' earnings last quarter? Odonate Therapeutics Inc (NASDAQ:ODT) posted its earnings results on Tuesday, October, 23rd. The company reported ($0.98) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.96) by $0.02. View Odonate Therapeutics' Earnings History. When is Odonate Therapeutics' next earnings date? Odonate Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Odonate Therapeutics. Has Odonate Therapeutics been receiving favorable news coverage? Media stories about ODT stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Odonate Therapeutics earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the near term. Who are some of Odonate Therapeutics' key competitors? Some companies that are related to Odonate Therapeutics include Mallinckrodt (MNK), Portola Pharmaceuticals (PTLA), Vanda Pharmaceuticals (VNDA), Pacira Pharmaceuticals (PCRX), Zai Lab (ZLAB), Theravance Biopharma (TBPH), Enanta Pharmaceuticals (ENTA), The Medicines (MDCO), Prestige Consumer Healthcare (PBH), Cambrex (CBM), Biohaven Pharmaceutical (BHVN), Aimmune Therapeutics (AIMT), Arrowhead Pharmaceuticals (ARWR), Nabriva Therapeutics (NBRV) and Phibro Animal Health (PAHC). Who are Odonate Therapeutics' key executives? Odonate Therapeutics' management team includes the folowing people: Mr. Kevin C. Tang, Chairman & CEO (Age 52)Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)Mr. John G. Lemkey, Chief Operating Officer (Age 38)Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43) When did Odonate Therapeutics IPO? (ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager. How do I buy shares of Odonate Therapeutics? Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Odonate Therapeutics' stock price today? One share of ODT stock can currently be purchased for approximately $17.55. How big of a company is Odonate Therapeutics? Odonate Therapeutics has a market capitalization of $437.02 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe. What is Odonate Therapeutics' official website? The official website for Odonate Therapeutics is http://www.odonate.com. How can I contact Odonate Therapeutics? Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected] MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 77 (Vote Outperform)Underperform Votes: 106 (Vote Underperform)Total Votes: 183MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: How does the Federal Reserve determine interest rates?